Miniatura

Fitxers

s41408-021-00417-3.pdf (1.35 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2021-02-01

Llicència de publicació

cc by (c) Barbui et al., 2021
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/175067

Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1038/s41408-021-00417-3

Resum

In a multicenter European retrospective study including 162 patients with COVID-19 occurring in essential thrombocythemia (ET, n = 48), polycythemia vera (PV, n = 42), myelofibrosis (MF, n = 56), and prefibrotic myelofibrosis (pre-PMF, n = 16), 15 major thromboses (3 arterial and 12 venous) were registered in 14 patients, of whom all, but one, were receiving LMW-heparin prophylaxis. After adjustment for the competing risk of death, the cumulative incidence of arterial and venous thromboembolic events (VTE) reached 8.5% after 60 days follow-up. Of note, 8 of 12 VTE were seen in ET. Interestingly, at COVID-19 diagnosis, MPN patients had significantly lower platelet count (p < 0.0001) than in the pre-COVID last follow-up.This decline was remarkably higher in ET (-23.3%, p < 0.0001) than in PV (-16.4%, p = 0.1730) and was associated with higher mortality rate (p = 0.0010) for pneumonia. The effects of possible predictors of thrombosis, selected from those clinically relevant and statistically significant in univariate analysis, were examined in a multivariate model. Independent risk factors were transfer to ICU (SHR = 3.73, p = 0.029), neutrophil/lymphocyte ratio (SHR = 1.1, p = 0.001) and ET phenotype (SHR = 4.37, p = 0.006). The enhanced susceptibility to ET-associated VTE and the associated higher mortality for pneumonia may recognize a common biological plausibility and deserve to be delved to tailor new antithrombotic regimens including antiplatelet drugs.

Matèries

Leucèmia mieloide, Trombosi, COVID-19

Matèries (anglès)

Myeloid leukemia, Thrombosis, COVID-19

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

BARBUI, Tiziano, STEFANO, Valerio de, ÁLVAREZ LARRÁN, Alberto, IURLO, Alessandra, MASCIULLI, Arianna, CAROBBIO, Alessandra, GHIRARDI, Arianna, FERRARI, Alberto, CANCELLI, Valeria, ELLI, Elena maria, ANDRADE CAMPOS, Marcio miguel, GASIOR KABAT, Mercedes, KILADJIAN, Jean-jacques, PALANDRI, Francesca, BENEVOLO, Giulia, GARCIA GUTIERREZ, Valentin, FOX, Maria laura, FONCILLAS, Maria angeles, MORCILLO, Carmen montoya, RUMI, Elisa, OSORIO, Santiago, PAPADOPOULOS, Petros, BONIFACIO, Massimiliano, QUIROZ CERVANTES, Keina susana, SERRANO, Miguel sagues, CARREÑO TARRAGONA, Gonzalo, SOBAS, Marta anna, LUNGHI, Francesca, PATRIARCA, Andrea, ELORZA, Begoña navas, ANGONA, Anna, MAZO, Elena magro, KOSCHMIEDER, Steffen, CARLI, Giuseppe, CUEVAS, Beatriz, HERNANDEZ BOLUDA, Juan carlos, ABADIA, Emma lopez, XICOY CIRICI, Blanca, GUGLIELMELLI, Paola, GARROTE I ORDEIG, Marta, CATTANEO, Daniele, DAFFINI, Rosa, CAVALCA, Fabrizio, BELLOSILLO, Beatriz, BENAJIBA, Lina, CURTO GARCIA, Natalia, BELLINI, Marta, BETTI, Silvia, HARRISON, Claire, RAMBALDI, Alessandro, VANNUCCHI, Alessandro maria. Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19. _Blood Cancer Journal_. 2021. Vol. 11. [consulta: 21 de gener de 2026]. [Disponible a: https://hdl.handle.net/2445/175067]

Exportar metadades

JSON - METS

Compartir registre